Deutsche Bank Aktiengesellschaft Lowers Haleon (LON:HLN) Price Target to GBX 335

Haleon (LON:HLN) had its target price dropped by stock analysts at Deutsche Bank Aktiengesellschaft from GBX 340 to GBX 335 in a research note issued to investors on Thursday, Marketbeat.com reports. The firm presently has a “buy” rating on the stock. Deutsche Bank Aktiengesellschaft’s price objective would suggest a potential downside of 11.80% from the company’s previous close.

HLN has been the topic of a number of other reports. JPMorgan Chase & Co. upped their price target on Haleon from GBX 315 to GBX 335 and gave the stock an “underweight” rating in a research note on Wednesday, November 26th. Royal Bank Of Canada reaffirmed a “sector perform” rating and set a GBX 370 target price on shares of Haleon in a research report on Friday, October 31st. Berenberg Bank lifted their price target on shares of Haleon from GBX 507 to GBX 517 and gave the company a “buy” rating in a research report on Wednesday, November 5th. Finally, Jefferies Financial Group restated a “buy” rating and set a GBX 450 price target on shares of Haleon in a research note on Wednesday. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of GBX 407.83.

Haleon Stock Performance

LON:HLN opened at GBX 379.80 on Thursday. The firm has a market capitalization of £33.83 billion, a P/E ratio of 22.74, a P/E/G ratio of 1.49 and a beta of 0.19. Haleon has a twelve month low of GBX 325.10 and a twelve month high of GBX 419.50. The company has a fifty day moving average of GBX 368.78 and a 200-day moving average of GBX 359.38. The company has a quick ratio of 0.93, a current ratio of 0.84 and a debt-to-equity ratio of 53.36.

Haleon Company Profile

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.